Diplomat Pharmacy (NYSE:DPLO) had its price objective reduced by Mizuho to $18.00 in a research report released on Friday, The Fly reports. Mizuho currently has a neutral rating on the stock.

Several other research analysts have also weighed in on DPLO. ValuEngine lowered shares of Diplomat Pharmacy from a hold rating to a sell rating in a research note on Wednesday, September 12th. Zacks Investment Research lowered shares of Diplomat Pharmacy from a hold rating to a sell rating in a research note on Tuesday, October 23rd. Robert W. Baird lowered shares of Diplomat Pharmacy from a neutral rating to an underperform rating and reduced their price objective for the stock from $22.00 to $10.00 in a research note on Wednesday. Finally, Wells Fargo & Co reduced their price objective on shares of Diplomat Pharmacy from $23.00 to $16.00 and set a market perform rating on the stock in a research note on Thursday. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average target price of $24.50.

Diplomat Pharmacy stock traded up $0.04 during midday trading on Friday, hitting $16.09. 1,694,581 shares of the stock were exchanged, compared to its average volume of 1,097,092. Diplomat Pharmacy has a 52 week low of $13.31 and a 52 week high of $28.74. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of 19.15 and a beta of 0.95. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.95 and a quick ratio of 0.63.

Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Tuesday, November 6th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.21). Diplomat Pharmacy had a return on equity of 5.31% and a net margin of 0.04%. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.42 billion. During the same period in the previous year, the business earned $0.01 EPS. The firm’s revenue was up 22.0% compared to the same quarter last year. As a group, analysts predict that Diplomat Pharmacy will post 0.81 EPS for the current fiscal year.

In other Diplomat Pharmacy news, Director Philip R. Hagerman sold 209,367 shares of Diplomat Pharmacy stock in a transaction that occurred on Thursday, September 13th. The shares were sold at an average price of $19.07, for a total value of $3,992,628.69. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Philip R. Hagerman sold 57,500 shares of Diplomat Pharmacy stock in a transaction that occurred on Tuesday, September 11th. The shares were sold at an average price of $19.21, for a total transaction of $1,104,575.00. The disclosure for this sale can be found here. Insiders own 24.70% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Swiss National Bank lifted its position in shares of Diplomat Pharmacy by 8.2% in the second quarter. Swiss National Bank now owns 90,200 shares of the company’s stock worth $2,306,000 after purchasing an additional 6,800 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Diplomat Pharmacy by 147.5% in the second quarter. SG Americas Securities LLC now owns 12,820 shares of the company’s stock worth $328,000 after purchasing an additional 7,640 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its position in shares of Diplomat Pharmacy by 6.7% in the second quarter. Metropolitan Life Insurance Co. NY now owns 43,782 shares of the company’s stock worth $1,119,000 after purchasing an additional 2,746 shares in the last quarter. Louisiana State Employees Retirement System lifted its position in shares of Diplomat Pharmacy by 15.3% in the third quarter. Louisiana State Employees Retirement System now owns 24,900 shares of the company’s stock worth $483,000 after purchasing an additional 3,300 shares in the last quarter. Finally, Brown Advisory Inc. bought a new stake in shares of Diplomat Pharmacy in the first quarter worth $466,000. 82.05% of the stock is currently owned by hedge funds and other institutional investors.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Featured Article: How Investors Use a Balance Sheet

The Fly

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.